Alzheimer’s disease (AD) is a growing global health concern, but current drug therapies have shown limited effectiveness for symptom management and disease modification. Medium chain triglycerides (MCTs) have emerged as a potential nutritional therapy, but evidence remains inconclusive. Key Facts: MCTs may provide an alternative brain fuel source and reduce AD biomarkers like amyloid-beta. Small …
A new drug recently approved for Alzheimer’s disease aims to treat the underlying cause of the condition by removing amyloid plaques in the brain. Though promising, the drug called aducanumab also comes with potential side effects that require careful monitoring. Key facts: Aducanumab is the first drug that targets and removes amyloid plaques, sticky buildups …
Experiencing chronic stress or taking addictive drugs like cocaine can change your brain and behavior in similar ways, making you prone to anxiety or addiction. Key Facts: Chronic stress and chronic drug abuse both impair the striatum, which can make people become rigid in their thinking and unable to update information. This can promote anxiety, …
A new large genetics study has discovered new clues into how levels of a protein called apolipoprotein E (ApoE) in the blood may influence a person’s risk of developing Alzheimer’s disease. Key facts: Researchers found 9 new genetic variants that influence ApoE levels in the blood. Some raise levels, while others lower levels. People with …
A new study published in Nature Medicine has identified two biological profiles, based on routine blood tests during COVID-19 hospitalization, that can predict patients’ risk of developing post-COVID brain fog months later. Key Facts: The study analyzed data from over 1,800 COVID-19 patients hospitalized in the UK. It linked certain patterns of blood biomarkers during …
